CUPERTINO, Calif., Sept. 4,
2024 /PRNewswire/ -- DURECT Corporation (Nasdaq:
DRRX), a late-stage biopharmaceutical company pioneering the
development of epigenetic therapies to transform the treatment of
serious and life-threatening conditions such as acute organ injury
and cancer, today announced management's participation in the H.C.
Wainwright 26th Annual Global Investment Conference to
take place September 9-11, 2024 in
New York City.
Management will also be available for virtual 1×1 meetings from
September 9-11, 2024 during the
conference. If attendees would like to request a meeting, please
contact H.C. Wainwright directly.
About DURECT Corporation
DURECT is a late-stage
biopharmaceutical company pioneering the development of epigenetic
therapies that target dysregulated DNA methylation to transform the
treatment of serious and life-threatening conditions, including
acute organ injury and cancer. Larsucosterol, DURECT's lead drug
candidate, binds to and inhibits the activity of DNA
methyltransferases (DNMTs), epigenetic enzymes that are elevated
and associated with hypermethylation found in alcohol-associated
hepatitis (AH) patients. Larsucosterol is in clinical development
for the potential treatment of AH, for which the FDA has granted
Fast Track and Breakthrough Therapy designation; metabolic
dysfunction-associated steatohepatitis (MASH) is also being
explored. In addition, POSIMIR® (bupivacaine
solution) for infiltration use, a non-opioid analgesic utilizing
the innovative SABER® platform technology, is
FDA-approved and is exclusively licensed to Innocoll
Pharmaceuticals for sale and distribution in the United States. For more information about
DURECT, please visit www.durect.com and follow us on X
(formerly Twitter) at https://x.com/DURECTCorp.
DURECT Forward-Looking Statements
This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, relating to: the potential to
develop larsucosterol for AH, MASH or other indications, and the
potential uses and benefits, if any, of our product candidates.
Actual results may differ materially from those contained in the
forward-looking statements contained in this press release, and
reported results should not be considered as an indication of
future performance. The potential risks and uncertainties that
could cause actual results to differ from those projected include,
among other things, the risks that the Company is unable to raise
sufficient capital to commence the Phase 3 trial of larsucosterol
in AH, trial enrollment or completion takes longer than
anticipated, future clinical trials of larsucosterol are
delayed or do not confirm the results from subset analyses of the
AHFIRM trial, including geographic or other segmentation, or of
earlier clinical or pre-clinical trials, or do not demonstrate the
safety or efficacy of larsucosterol in a statistically significant
manner; the risk that the FDA or other government agencies may
require additional clinical trials for larsucosterol before
approving larsucosterol for the treatment of AH, and that
larsucosterol may never be approved; and risks related to the
sufficiency of our cash resources, our anticipated capital
requirements, our need or desire for additional financing, our
ability to continue to meet the minimum bid price for continued
listing on Nasdaq, our ability to obtain capital to fund our
operations and expenses, and our ability to continue to operate as
a going concern. Further information regarding these and other
risks is included in DURECT's most recent Securities and Exchange
Commission (SEC) filings, including its annual report on Form 10-K
for the year ended December 31, 2023 and quarterly report on
Form 10-Q for the quarter ended June 30, 2024 under the
heading "Risk Factors." These reports are available on our
website www.durect.com under the "Investors" tab and on
the SEC's website at www.sec.gov. All information provided in
this press release and in the attachments is based on information
available to DURECT as of the date hereof, and DURECT assumes no
obligation to update this information as a result of future events
or developments, except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll
Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT
Corporation outside of the U.S. SABER® is a trademark of
DURECT Corporation. Other referenced trademarks belong to their
respective owners. Larsucosterol is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities for any indication.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-the-hc-wainwright-global-investment-conference-302238471.html
SOURCE DURECT Corporation